Somewhat Favorable Media Coverage Somewhat Unlikely to Affect Corcept Therapeutics (CORT) Stock Price
Headlines about Corcept Therapeutics (NASDAQ:CORT) have been trending somewhat positive on Saturday, Accern reports. Accern ranks the sentiment of media coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Corcept Therapeutics earned a media sentiment score of 0.15 on Accern’s scale. Accern also gave headlines about the biotechnology company an impact score of 46.264407523437 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
These are some of the headlines that may have impacted Accern Sentiment’s scoring:
- Bogle Investment Management L P DE Has $12.75 Million Holdings in Corcept Therapeutics Incorporated (CORT) (americanbankingnews.com)
- Corcept Therapeutics Incorporated (CORT) Position Cut by Globeflex Capital L P (americanbankingnews.com)
- Analyzing Amgen (AMGN) and Corcept Therapeutics (CORT) (americanbankingnews.com)
- Corcept Therapeutics Incorporated (CORT) Shares Sold by Arrowstreet Capital Limited Partnership (americanbankingnews.com)
- Fuller & Thaler Asset Management Inc. Has $7.95 Million Position in Corcept Therapeutics Incorporated (CORT) (americanbankingnews.com)
Corcept Therapeutics (NASDAQ:CORT) opened at $14.96 on Friday. The firm has a market cap of $1,730.00, a P/E ratio of 11.69 and a beta of 2.02. Corcept Therapeutics has a 52 week low of $8.90 and a 52 week high of $25.96.
Several equities analysts have recently weighed in on the stock. BidaskClub cut shares of Corcept Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, February 13th. Piper Jaffray Companies set a $30.00 price target on shares of Corcept Therapeutics and gave the stock a “buy” rating in a research note on Monday, February 5th. Stifel Nicolaus decreased their price target on shares of Corcept Therapeutics from $25.00 to $20.00 and set a “buy” rating for the company in a research note on Monday, February 5th. Finally, Zacks Investment Research cut shares of Corcept Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, January 3rd. Two research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $21.00.
In other news, insider Robert S. Fishman sold 8,000 shares of the firm’s stock in a transaction that occurred on Friday, December 8th. The shares were sold at an average price of $16.72, for a total transaction of $133,760.00. Following the completion of the transaction, the insider now directly owns 8,000 shares of the company’s stock, valued at approximately $133,760. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Insiders have sold a total of 24,000 shares of company stock valued at $415,920 over the last ninety days. Company insiders own 19.20% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “Somewhat Favorable Media Coverage Somewhat Unlikely to Affect Corcept Therapeutics (CORT) Stock Price” was originally published by Watch List News and is the sole property of of Watch List News. If you are accessing this article on another publication, it was stolen and reposted in violation of US and international trademark & copyright laws. The correct version of this article can be viewed at https://www.watchlistnews.com/somewhat-favorable-media-coverage-somewhat-unlikely-to-affect-corcept-therapeutics-cort-stock-price/1903509.html.
Corcept Therapeutics Company Profile
Corcept Therapeutics Incorporated is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. The Company is developing mifepristone, a compound that modulates the effects of cortisol by acting as a competitive antagonist at the glucocorticoid receptor (GR).
Receive News & Ratings for Corcept Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corcept Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.